|HUG project leader||Laurence Toutous Trellu, ,|
|Department, division||Service de dermatologie, HUG / /|
|Project partner abroad||Matthew Coldiron, Jean Paul Kimenyi, Lucas Molfino|
|Department, division||Epicentre- Médecins sans frontières / Médicos Sem Frontereiras / Médicos sem fronteiras|
|Institution||Médecins sans frontières / Médecins sans frontières Suisse / Médecins sans frontières Suisse|
|firstname.lastname@example.org, MSFCH-Maputoemail@example.com, firstname.lastname@example.org|
|Kaposi’s sarcoma (KS) is endemic in many countries of Africa and causes considerable morbidity and mortality in sub-Saharan Africa. The association with HIV infection and loss of immunity worsens the presentation of this tumor known to be associated to Herpes virus 8 (HHV8). Few treatment programs can effectively combat this burden. Some of the reasons for the lack of KS treatment programs are the absence of international guidelines and protocols adapted for resource deprived settings as well as high cost of modern treatment.
We propose to introduce a new treatment for Kaposi’s Sarcoma patients at the MSF-CH supported Centro de Referencia do Alto-Maé in Maputo, Mozambique. Specifically, MSF-CH with approval of the Ministry of Health, proposes to substitute the standard therapy of doxorubicin, bleomycin and vincristine (ABV) with pegylated liposomal doxorubicin (PLD), which in clinical trials has been shown to be less toxic and more effective than the standard therapy, but not yet widely used in resource limited settings due to its high costs.
Since PLD is not yet used in Mozambique, we here propose to implement it as part of a clinical study with the objective to document its effectiveness and safety in a resource-limited setting.